Press Release | Mon Aug 29, 2011 1:01am EDT

Actelion reports results of exploratory study with macitentan in IPF patients - promising long-term safety and tolerability profile - efficacy data not supportive of Phase III in IPF

* Reuters is not responsible for the content in this press release.